|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.06.26 - 22:03
|
Lakefront Announces Initiation of €50 Million Stock Repurchase Program (GlobeNewswire EN)
|
|
|
Mechelen, Belgium; June 9, 2026, 22:01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), under which the Company may repurchase ordinary shares for an aggregate amount of up to €50 Million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into with Morgan Stanley & Co International PLC. ...
|
|
|
08.06.26 - 22:03
|
Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer (GlobeNewswire EN)
|
|
|
Mechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company's strategic transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026.1 Eric will report to Henry Gosebruch, CEO and join the Company's Management Committee....
|
|
|
|
|
|
|
|
|
06.05.26 - 22:03
|
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire EN)
|
|
|
Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM (Euronext & NASDAQ: LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation prioritiesYear-end 2026 cash and financial investments balance expected to be approximately €2BManagement to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ETMechelen, Belgium; May 6, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the first quarter of 2026 and provided a business update.“Having joined the company just one year ago, I'm thrilled with our progress. I am looking forward to consummating our partnership with Gilead and addin...
|
|
|
|
|
|